eamdacademy.org-l0fr-1793276189-b470339053 1793276189 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 2 Claire Martin Julien Robert 2026 10.68159/b470339053 https://eamdacademy.org/pub/journal/3/article/b470339053 Siegel R, Giaquinto A, Jemal A. Cancer statistics, 2024. Cancer J Clin. 2024;74(1):12-49. 10.3322/caac.21820 Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229-63. 10.3322/caac.21834 Micheli A, Baili P, Quinn M, Mugno E, Capocaccia R, Grosclaude P, et al. Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas. Ann Oncol. 2023;14:v28-40. Yourman L, Bergstrom J, Bryant E, Pollner A, Moore A, Schoenborn N, et al. Variation in receipt of cancer screening and immunizations by 10-year life expectancy among US adults aged 65 or older in 2019. J Gen Int Med. 2024;39(3):440-9. Brown R, Bigelow P, Dubin J, Neiterman E. Breast cancer, alcohol, and phosphate toxicity. J Appl Toxicol. 2024;44(1):17-27. 10.1002/jat.4504 Oze I, Ito H, Koyanagi Y, Abe S, Rahman M, Islam M, et al. Obesity is associated with biliary tract cancer mortality and incidence: A pooled analysis of 21 cohort studies in the Asia Cohort Consortium. Int J Cancer. 2024;154(7):1174-90. 10.1002/ijc.34794 Jones A, Scheurlen K, Macleod A, Simon H, Galandiuk S. Obesity and inflammatory factors in the progression of early-onset colorectal cancer. Cancers. 2024;16(7):1403. 10.3390/cancers16071403 Trivilin L, Mendes S, Borçoi A, Cassiano D, Archanjo A, De- Oliveira M, et al. In vivo model of colorectal cancer: impact to cigarette smoke exposition on neoplasm development. Peer Rev. 2024;6(8):70-86. 10.53660/PRW-2071-3812 Mei J, Qian M, Hou Y, Liang M, Chen Y, Wang C, et al. Association of saturated fatty acids with cancer risk: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):32. Dao TL, Hilf R. Dietary fat and breast cancer: a search for mechanisms. Exer Calor Fat Cancer. 2024:223-37. Wan Y, Wu K, Wang L, Yin K, Song M. Dietary fat and fatty acids in relation to risk of colorectal cancer. Eur J Nut. 2022;61(4):1863-73. 10.1007/s00394-021-02777-9 Usui Y, Taniyama Y, Endo M, Koyanagi Y, Kasugai Y, Oze I, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. New Eng J Med. 2023;388(13):1181-90. Horackova K, Janatova M, Kleiblova P, Kleibl Z, Soukupova J. Early-onset ovarian cancer< 30 years: what do we know about its genetic predisposition? Int J Mol Sci. 2023;24(23):17020. Breast Cancer Association Consortium. Breast cancer risk genes-association analysis in more than 113,000 women. New Engl J Med. 2021;384(5):428-39. Kasi P, Lee J, Pasquina L, Decker B, Vanden P, Pavlick D, et al. Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types. Clin Cancer Res. 2024;30(4):836-48. 10.1158/1078-0432.CCR-23-2693 Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024;30(3):730-9. Sosinsky A, Ambrose J, Cross W, Turnbull C, Henderson S, Jones L, et al. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. Nat Med. 2024;30(1):279-89. Pineda-Lancheros L, Gálvez-Navas J, Rojo-Tolosa S, Membrive-Jiménez C, Valverde-Merino M, Martínez-Martínez F, et al. Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 genes as biomarkers of survival in non-small cell lung cancer: a systematic review. Nutrients. 2023;15(6):1525. Hayama T, Hashiguchi Y, Okamoto K, Okada Y, Ono K, Shimada R. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. Int J Colorectal Dis. 2019;34:1491-6. 10.1007/s00384-019-03344-9 Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024;21(3):1-18. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55-62. 10.5858/2010-0454-RAR.1 Duffy M, O'Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Trea Rev. 2021;94:102154. 10.1016/j.ctrv.2021.102154 Dhiwar P, Purawarga G, Pal R, Singh E, Ghara A, Maji L, et al. An assessment of EGFR and HER2 inhibitors with structure-activity relationship of fused pyrimidine derivatives for breast cancer: a brief review. J Biomol Struct Dyn. 2024;42(3):1564-81. 10.1080/07391102.2023.2204351 Jia J, Zhou X, Chu Q. Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer. Mol Cell Biochem. 2024:1-17. Lai K, Jin Y, Graham D, Witthuhn B, Ihle J, Liu E. A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells (∗). J Biol Chem. 1995;270(42):25028-36. 10.1074/jbc.270.42.25028 Hu Q, Dou N, Wu Q, Gao Y, Li Y, Chen J. JAK3/STAT5 signaling‐triggered upregulation of PIK3CD contributes to gastric carcinoma development. J Cell Comm Signal. 2024;18(1);e12017. 10.1002/ccs3.12017 Li S, Ma M, Li H, Waluszko A, Sidorenko T, Schadt E, et al. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Med. 2017;9:1-11. Vadivel C, Gluud M, Torres-Rusillo S, Boding L, Willerslev-Olsen A, Buus T, et al. JAK3 is expressed in the nucleus of malignant T cells in cutaneous T cell lymphoma (CTCL). Cancers. 2021;13(2):280. 13020280 10.3390/cancers Jeong E, Kim M, Nam H, Min C, Lee S, Chung Y, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14(12):3716-21. 10.1158/1078-0432.CCR-07-4839 Lv Y, Mi P, Babon J, Fan G, Qi J, Cao L, et al. Small molecule drug discovery targeting the JAK-STAT pathway. Pharmacol Res. 2024;107217. 10.1016/j.phrs.2024.107217 Taylor P, Choy E, Baraliakos X, Szekanecz Z, Xavier R, Isaacs J, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology. 2024;63(2):298-308. Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares G, Vangrevelinghe E, et al. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J Med Chem. 2011;54(1):284-8. 10.1021/jm101157 Lopez-Ramos M, Figueroa-Valverde L, Alvarez-Ramirez M, Rosas-Nexicapa M, Mateu-Armand M, Cauich-Carrillo R. Interaction of eight steroid derivatives with VEGFR-1 using a theoretical model. Braz J Sci. 2024;3(3):11-24. 10.14295/bjs.v3i3.523 Figueroa-Valverde L, Rosas-Nexticapa M, Alvarez-Ramirez M, López-Ramos M, Díaz-Cedillo F, Mateu-Armad M. Evaluation of biological activity exerted by Dibenzo [b, e] Thiophene-11 (6H)-One on left ventricular pressure using an isolated rat heart model. Drug Res. 2023;73(05):263-70. 10.1055/a-1995-6351 Figueroa-Valverde L, Díaz-Cedillo F, Rosas-Nexticapa M, Alvarez-Ramirez M, Mateu-Armad M, López-Ramos M. Interaction of some amino-nitrile derivatives with vascular endothelial growth factor receptor 1 (VEGFR1) using a theoretical model. Drug Res. 2023;73(06):355-64. 10.1055/a-2062-3571 Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D, et al. Alectinib in resected ALK-positive non–small-cell lung cancer. New Engl J Med. 2024;390(14):1265-76. 10.1056/NEJMoa2310532 Olszewski M, Maciejewska N Kallingal A, Chylewska A, Dąbrowska A, Biedulska M, et al. Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction. J Enzyme Inh Med Chem. 2024;39(1):2302920. 10.1080/14756366.2024.2302920 Kolli S, Prasad B, Babu P. TFAA/H3PO4 mediated unprecedented N-acylation of carbazoles leading to small molecules possessing anti-proliferative activities against cancer cells. Org Biomol Chem. 2014;12(32):6080-4. 10.1039/C4OB00686K Kumar T, Mahadevan K, Kumara M. Synthesis and cytotoxic studies of 2, 3-dimethylindoles and tetrahydrocarbazoles. Int J Pharm Pharm Sci. 2014;6(2):137-40. Yoon S, Kim J-H, Lee Y. A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage. Eur J Pharmacol. 2012;697(1-3):24-31. Serdaroğlu G, Uludağ N, Ercag E, Sugumar, Rajkumar P. Carbazole derivatives: Synthesis, spectroscopic characterization, antioxidant activity, molecular docking study, and the quantum chemical calculations. J Mol Liquids. 2021;330:115651. 10.1016/j.molliq.2021.115651 Çapan İ, Hawash M, Jaradat N, Sert Y, Servi R, Koca İ. Design, synthesis, molecular docking, and biological evaluation of new carbazole derivatives as anticancer, and antioxidant agents. BMC Chem. 2023;17(1):60. 10.1186/s13065-023-00961-y Patel M, Pandey N, Timaniya J, Parikh P, Chauhan A, Jain N, et al. Coumarin–carbazole based functionalized pyrazolines: Synthesis, characterization, anticancer investigation and molecular docking. RSC Adv. 2021;11(44):27627-44. 10.1039/D1RA03970A Sungthong B, Sithon K, Panyatip P, Tadtong S, Nunthaboot N, Puthongking P. Quantitative analysis and in silico molecular docking screening for acetylcholinesterase inhibitor and ADME prediction of coumarins and carbazole alkaloids from Clausena harmandiana. Nat Prod. 2022;16(4):358-69. Kapetanovic I, Muzzio M, Hu S, Crowell J, Rajewski R, Haslam J, et al. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemother Pharmacol. 2010;65:1109-16. Ahlström M, Ridderström M, Zamora I. CYP2C9 structure-metabolism relationships: Substrates, inhibitors, and metabolites. J Med Chem. 2007;50(22):5382-91. 10.1021/jm070745g Daly A, Rettie A, Fowler D, Miners J. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017;8(1):1. 10.3390/jpm8010001 Liu Y, Jin X, Ye Y, Xu Z, Du Z, Hong H, et al. Emerging disinfection byproducts 3-bromine carbazole induces cardiac developmental toxicity via aryl hydrocarbon receptor activation in zebrafish larvae. Environm Poll. 2024;346:123609. 10.1016/j.envpol.2024.123609 Gabelova A. 7H-Dibenzo [c, g] carbazole: metabolic pathways and toxicity. Chem Biol Interact. 2020;323:109077. 10.1016/j.cbi.2020.109077